Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(100.0%)
1Total
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01845350Phase 1Completed

Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients

Role: lead

NCT01872299Completed

Studies Investigating Co-morbidities Aggravating Heart Failure

Role: collaborator

NCT02220387Completed

Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures

Role: collaborator

NCT02284295Completed

Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures 2

Role: collaborator

All 4 trials loaded